Charles Schwab Investment Management Inc. Has $25.23 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Charles Schwab Investment Management Inc. lifted its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 542,832 shares of the company's stock after buying an additional 17,890 shares during the period. Charles Schwab Investment Management Inc. owned about 0.91% of Twist Bioscience worth $25,225,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in TWST. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience in the third quarter valued at about $34,000. Van ECK Associates Corp lifted its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares during the period. US Bancorp DE lifted its stake in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after buying an additional 601 shares during the period. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience in the third quarter valued at about $95,000. Finally, KBC Group NV lifted its stake in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after buying an additional 1,226 shares during the period.

Insiders Place Their Bets

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of Twist Bioscience stock in a transaction on Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares of the company's stock, valued at approximately $965,531.49. The trade was a 13.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 2,402 shares of Twist Bioscience stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the sale, the chief executive officer now directly owns 662,692 shares of the company's stock, valued at $27,110,729.72. This represents a 0.36 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 31,552 shares of company stock valued at $1,500,289. Company insiders own 3.01% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of research analysts have commented on the stock. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Robert W. Baird raised their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. TD Cowen reiterated a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $54.40.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded up $0.84 during midday trading on Friday, reaching $42.89. The company had a trading volume of 1,319,967 shares, compared to its average volume of 924,314. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -12.69 and a beta of 2.15. The stock has a fifty day simple moving average of $45.40 and a 200 day simple moving average of $45.20. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience's revenue for the quarter was up 24.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.75) earnings per share. As a group, equities research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.